Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study

In this primary prevention cohort (n=2,196, mean age, 50.5 years; 55% female), statin-eligible participants (defined by 2013 ACC/AHA guidelines; n=812) have an increased risk of developing or dying as a result of cancer versus non–statin-eligible participants (n=1,384).

The following results were presented:

 

• Incident cancer occurred in 15% of statin-eligible participants versus 8.8% of non-eligible participants (HR, 1.8 [1.4 to 2.3]; P < 0.001).

 

• Cancer mortality occurred in 4.2% of statin-eligible participants versus 0.4% non-eligible participants (HR, 12.1 [4.7 to 31]; P < 0.001).

 

• Non-cardiovascular mortality occurred in 6.0% of statin-eligible participants versus 0.7% of non-eligible participants (HR, 10.1 [5.0 to 21]; P < 0.001).

 

• In stratified analyses, these findings were independent of any individual causative risk factor such as body mass index, age, or smoking status.